RPL13 Human shRNA Plasmid Kit (Locus ID 6137)

CAT#: TG301915

RPL13 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector

Specifications

Product Data

• Locus ID: 6137
• Synonyms: BBC1; D16S44E; D16S444E; L13
• Vector: pGFP-V-RS
• E. coli Selection: Kanamycin
• Mammalian Cell Selection: Puromycin
• Format: Retroviral plasmids
• Kit Components: RPL13 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 6137). 5µg purified plasmid DNA per construct
  Non-effective 29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free.
• RefSeq: NM_000977, NM_001243130, NM_001243131, NM_033251, BC010994, BC066320, BC093063, BC000851, BC004954, BC006179, BC007345, BC007563, BC007805, BC013078, BC014167, BC020804, BC027463, BC063378, BC106058
• Summary: 'Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a ribosomal protein that is a component of the 60S subunit. The protein belongs to the L13E family of ribosomal proteins. It is located in the cytoplasm. This gene is expressed at significantly higher levels in benign breast lesions than in breast carcinomas. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. [provided by RefSeq, Jul 2011]'
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).